Louisiana State Employees Retirement System Purchases Shares of 9,300 IDEXX Laboratories, Inc. $IDXX

Louisiana State Employees Retirement System acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,300 shares of the company’s stock, valued at approximately $5,226,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. SHP Wealth Management acquired a new position in IDEXX Laboratories in the 4th quarter worth $26,000. Virtus Advisers LLC acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at about $26,000. Park Place Capital Corp bought a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $29,000. WealthCollab LLC bought a new stake in shares of IDEXX Laboratories in the second quarter valued at about $30,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of IDEXX Laboratories during the third quarter worth about $36,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Down 0.6%

NASDAQ IDXX opened at $551.50 on Friday. IDEXX Laboratories, Inc. has a 12 month low of $506.91 and a 12 month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The stock has a 50 day moving average of $558.79 and a 200-day moving average of $614.78. The company has a market cap of $43.50 billion, a PE ratio of 40.61, a PEG ratio of 3.04 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Citigroup initiated coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. Finally, UBS Group cut their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.